Wednesday, July 8, 2026

Patent intelligence · US

US 11701421

Compositions and methods for stabilizing flaviviruses with improved formulations

granted A61KA61K2039/5254A61K2039/55505A61K2039/55511
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 1,436
Patent details — US 11701421
Jurisdiction
US
Status
granted
Grant date
Jul 18, 2023
Expiration
Jul 13, 2043
Claims
30
CPC classes
A61K, A61K2039/5254, A61K2039/55505, A61K2039/55511
View on Google Patents ↗

Quick answer

US 11701421 (Compositions and methods for stabilizing flaviviruses with improved formulations) is held by Takeda Vaccines, Inc.. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
30
CPC classes
A61K, A61K2039/5254, A61K2039/55505, A61K2039/55511, A61K2039/55516, A61K39/12

More from Takeda Vaccines, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 11701421?

US 11701421 (Compositions and methods for stabilizing flaviviruses with improved formulations) is held by Takeda Vaccines, Inc.. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11701421?

Takeda Vaccines, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 11701421 expire?

Our index shows an expiration date of Jul 13, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.